Aberrations in AR, E26 transformation-specific (ETS) family members, TP53, and phosphatase and tensin homolog (PTEN) are the most frequently detected in mCRPC [28,29], which suggests specific vulnerabilities of prostate cancer subgroups that may be amenable to dedicated targeted therapies. This evidence concerns the gene PTEN and prostate carcinoma.